On this page
What it is
A short peptide encoded within mitochondrial DNA rather than nuclear DNA — one of a small family of 'mitochondrial-derived peptides' identified over the last fifteen years.
How it is proposed to work
Proposed to act as a mitochondrial stress signal influencing AMPK activity and metabolic homeostasis. Endogenous levels change with exercise and age in observational human data.
Approved medical uses
None. MOTS-c has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Human observational2020
Plasma and muscle MOTS-c across age bands in healthy men
Finding. In 104 healthy men compared across three age bands, circulating MOTS-c was reduced with age, while skeletal muscle MOTS-c expression ran the other way: older (70-81 y) and middle-aged (45-55 y) men had around 1.5-fold higher muscle expression than young men (18-30 y). Muscle MOTS-c expression tracked slow-type fibre markers, which the authors read as consistent with the fast-to-slow fibre shift of aging rather than as a benefit. In the older men who gave biopsies, muscle MOTS-c showed no association with maximal leg-press load or with thigh cross-sectional area taken separately; a positive association appeared only when leg-press load was expressed relative to thigh cross-sectional area. The authors conclude that plasma and muscle MOTS-c are differentially regulated with aging.
Limitation. The abstract states age bands rather than a participant count, so no figure is recorded here. Observational and cross-sectional: it compares men in three age bands and measures endogenous peptide levels, so it cannot show that administering the peptide produces any benefit. Plasma and muscle MOTS-c moved in opposite directions with age, so a blood measurement does not stand in for tissue levels, and the older men who gave blood were a separate group from the older men who gave muscle biopsies and leg-press data. The one favourable-sounding result, the muscle-quality association, is with muscle expression rather than circulating peptide, rests on about 24 older men, and appeared only after leg-press load was normalised to thigh size, with both unnormalised measures null. Higher muscle MOTS-c here is a feature of older muscle, not of younger muscle. Two of the authors are consultants and shareholders of CohBar, Inc., a company developing mitochondrial-derived peptide therapeutics. The sample is healthy men only, and the authors state that further research is required to determine the molecular targets of endogenous MOTS-c in human muscle.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
- Animal2015
Mouse metabolic study of insulin resistance and diet-induced obesity
Finding. MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, with skeletal muscle reported as the primary target organ and AMPK activation as the proposed mechanism.
Limitation. Mouse metabolic models translate poorly to human metabolic disease, and this report describes prevention of age- and diet-related insulin resistance in mice rather than treatment of established disease. Animal numbers and treatment duration are not stated in the abstract, and no exercise or physical-performance endpoint was measured, so nothing here speaks to exercise capacity.
Potential safety concerns
- CautionInsufficient
No human safety dataset of adequate size or duration exists.
Known interactions and contraindication considerations
- Not characterised in humans.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Not approved as of 24 Jul 2026 | Not approved. Has appeared in compounding-category discussion, which is not approval. |
European Union EMA | Unapproved / investigational as of 1 Jun 2026 | No marketing authorisation. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | New-drug pathway would apply. Not approved for human use. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Energy, exercise capacity and metabolic support
What is run
Several times weekly, often pre-training, in blocks of a few weeks. Frequently tracked with wearable recovery metrics.
Their mechanistic reasoning
That mitochondrial-derived peptides act as metabolic stress signals influencing AMPK, and that since endogenous levels rise with exercise and fall with age, supplying them exogenously should reproduce the associated benefits.
Reported in the community’s own terms. Not our position.
Stacked with
- NAD+ precursors—General mitochondrial support on overlapping reasoning.
- Structured endurance training—The best-evidenced mitochondrial intervention available, and the likely confound.
Regimen shape
- Dose
- figure withheld
- Scale
- Milligram-scale
- Route
- Subcutaneous injection
- Frequency
- Several times weekly
- Timing
- Often pre-training
- Duration
- Blocks of a few weeks
Our read
The underlying discovery is genuinely interesting science. The reasoning inverts a correlation: levels rising with exercise is at least as consistent with these peptides being a marker of training status as a driver of its benefits. Administering a signal is not the same as producing the state that normally generates it. Wearable tracking compounds the problem, since those scores respond to sleep, alcohol and training load far more than to anything being tested.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Interest is high among longevity-focused users but actual reports are sparse and unremarkable, which is a meaningful gap between how much it is discussed and how much it is said to do.
Commonly reported as helping
- Improved perceived energy
- Better wearable recovery scores
- Improved training tolerance, reported vaguely
Also reported, when it goes wrong
- Most report nothing clearly attributable
- Cost relative to any perceived benefit
- Difficulty distinguishing effect from normal variation
Why these reports can mislead
Wearable recovery scores are the outcome most often cited and among the least suitable — they respond to sleep, alcohol, illness and training load far more than to anything being tested. People run these blocks during periods when they are also training and sleeping with more intent.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Hold training and sleep constant or you cannot attribute anything you observe.
- No human safety dataset of adequate size or duration.
Active clinical trials
No registered trials currently tracked for MOTS-c.
What remains unknown
The questions that would change our assessment if they were answered.
- Does exogenous administration reproduce anything seen with endogenous signalling?
- Is a correlation between circulating levels and health simply a marker of fitness rather than a cause of it?
References
- 1.D'Souza RF, Woodhead JST, Hedges CP, et al. Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men is associated with myofiber composition. Aging (Albany NY). 2020;12(6):5244-5258.PMID 32182209doi
- 2.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015.PMID 25738459doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Scheduled review. No change.
Spotted something wrong? Tell us — we publish corrections.